Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
06 February 2020 | Story Michelle Nöthling | Photo Johan Roux
Symposium bridges the gap between students, staff, and management
Students from the UFS, UCLA and VUA shared on their collective experience within higher education at the colloquium.

The Unit for Institutional Change and Social Justice at the University of the Free State (UFS) united with the University of California, Los Angeles (UCLA), and the Vrije Universiteit Amsterdam (VUA) on the Bloemfontein Campus in a symposium discussing ‘Fragility and Resilience: Facets, Features and (Trans)Formations in Higher Education’. “It is really the only conference that brings together support staff, academic staff, students, and upper administration management, which includes vice-chancellors, rectors, presidents, and provosts,” said Dr Dionne van Reenen, Senior Researcher in the Unit for Institutional Change and Social Justice, and convener of the event.

Dr Van Reenen further explained that, when it comes to matters such as policy changes, contact between these various groups at a university is crucial. In general, upper management has very little contact with students. Students would rather approach academic staff. In turn, academic staff members are often reluctant to approach support staff, since support staff are already burdened with administrative tasks. But, Dr Van Reenen continued, all these stakeholders actually need to move closer to each other, since the Academic Project goal is the same: delivering excellent-quality graduates and producing new knowledge. With this in mind, the symposium programme specifically included panel presentations and discussions by academic as well as support staff and students. What emanated from these discussions was a rich variety of topics speaking to various aspects of fragility and resilience. The following are only a few excerpts from these engaging dialogues. 

Using counter-stories to narrate fragilities and resilience in higher education institutions in South Africa

Dr Fumane Khanare, Dr Ntombizandile Gcelu, and Pearl Larey – all three academic staff members in the UFS School of Education Studies, and Lihle Ndlovu, Head of Department for Business Studies at the uMfolozi TVET College – use narratives to interrogate fragility and resilience among black women in higher education. They wanted to go beyond surface conversations about how each was doing and decided to use critical race theory to question even their own stories through collaborative learning. They share, listen, question, and reflect, and as a result, create new narratives through counter-stories. “We are trying to explore our narratives,” Dr Khanare said, “not only as the outsiders, but as the insiders as well. From our background, we cannot ignore that we came here full of potential, but full of fragilities as well.” 

The ambiguity of change: The stories that South African student narratives tell 
Continuing the exploration of narratives, Dr Frans Kamsteeg from the Department of Sciences at VUA shared his research among students of the UFS who were part of the Leadership for Change programme. The programme, that came to an end in 2016, took UFS students through a process of leadership courses and training and included a trip to one of the external participating foreign universities. Dr Kamsteeg subsequently received several groups at the VUA and became interested in how these students engage in transformation processes at the UFS. Presenting seven vignettes of students’ narratives, Dr Kamsteeg revealed a tapestry of multivocality and fragility, and a meandering path of self-identity and transformation. “They learned a lot about academic citizenship and becoming responsible citizens,” Dr Kamsteeg added.

Keeping up with changing times: Student leaders, resilience, fragility, and professional development

Dr Marguerite Muller, Pulane Malefane, and Liezl Dick were all residence heads at the UFS. During the #FeesMustFall period, they realised that the role of student leaders had begun to change. They saw how these roles evolved and became interested in how student leaders became stakeholders and decision makers at the UFS. An interesting outcome from the arts-based research was that in the individual drawing exercise – in which students had to represent their lives as a winding river – fragility did not feature at all. Instead, the student leaders chose to depict sources of challenges and support, and how these factors built resilience. However, in the group exercise where students had to stage a puppet show, the stories revealed clear areas of fragility. Essentially, the students were willing to show fragility as long as they were fragile with others. “What we learned was that it is really important for student leaders to understand the complexity of their roles. Student leaders also need to learn and understand that it is okay to fail, that you need to grow and need to change, and that fragility in this sense is not necessarily a weakness,” Dr Muller concluded.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept